drugset / Trial / NCT01101841

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

NCT01101841

Phase 3 Completed 570 enrolled Noven Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause

Timeline

Start
2010-03
Primary completion
2011-09
Completion
2011-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 7.5 mg

Indications

No indication recorded.